ChristopherWalterRyanMD

Oncology • Portland, OR

Professor of Medicine, Oregon Health and Science University, Knight Cancer Institute

Join to view full profile

Dr. Ryan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Ryan's full profile

Already have an account?

Office
3303 Sw Bond Ave
7th Floor
Portland, OR 97239
Phone+1 503-494-6594
Is this information wrong?

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 1997 - 2000
University of ChicagoResidency, Internal Medicine, 1994 - 1997
SUNY Upstate Medical UniversityClass of 1994

Certifications & Licensure

ID State Medical License 2021 - 2025
OR State Medical License 2003 - 2025
IL State Medical License 1994 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Sorafenib, Epirubicin, Ifosfamide, and Radiation Therapy Followed By Surgery in Treating Patients With High-Risk Stage II or Stage III Soft Tissue Sarcoma Start of enrollment: 2009 Feb 01
Completed
Phase 1
S0931, Everolimus in Treating Patients With Kidney Cancer Who Have Undergone Surgery Start of enrollment: 2011 Apr 01
Active, not recruiting
Phase 3
Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma Start of enrollment: 2012 Apr 01
Completed
Not Applicable
Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma Start of enrollment: 2012 Mar 13
Completed
Phase 2
Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery Start of enrollment: 2012 Aug 08
Active, not recruiting
Phase 3
Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Start of enrollment: 2014 Jan 01
Completed
Phase 3
Sorafenib Tosylate, Combination Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma Start of enrollment: 2013 Dec 03
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancer.
Guadarrama, E., Ferri, W., Othus, M., Lopez, G., Patel, S., Chae, Y., Dennis, M., Powers, B., Liao, C., George, T., Sharon, E., Ryan, C., Blanke, C., Kurzrock, R.> ;Cancer. 2024 Feb 15
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609 Cohort 47) in Patients with Gestational Trophoblastic Neoplasia.
Megan Othus, David Mutch, Wolfram Samlowski, Elad Sharon, Gabby Lopez, Melissa Plets, Patel, S., Chae, Y., Dennis, M., Gordon, S., Robinson, W., Ryan, C., Blanke, C., ...> ;Clinical Cancer Research. 2024 Jan 5
4 citations
Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial.
Christopher W Ryan, Catherine M Tangen, Elisabeth I Heath, Mark N Stein, Maxwell V Meng, Ajjai S Alva, Sumanta K Pal, Igor Puzanov, Joseph I Clark, Toni K Choueiri, Ne...> ;Lancet. 2023 Sep 23
6 citations
A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastat...
Evan Rosenbaum, Rashmi Chugh, Christopher W Ryan, Mark Agulnik, Mohammed M Milhem, Suzanne George, Robin L Jones, Bartosz Chmielowski, Brian A Van Tine, Hussein Tawbi,...> ;European Journal of Cancer. 2022 Nov 1
7 citations
A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results.
Steven Attia, Vanessa Bolejack, Kristen N Ganjoo, Suzanne George, Mark Agulnik, Daniel Rushing, Elizabeth T Loggers, Michael B Livingston, Jennifer Wright, Sant P Chaw...> ;Cancer Medicine. 2023 Jan 1
14 citations
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial.
Mrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, Sant Chawla, Javier Martin-Broto, Giovanni Grignani, Scott M Schuetze, Bruno Vincenzi, Andrew J Wagner, Bartosz ...> ;Journal of Clinical Oncology. 2022 Aug 1
1 citations
A Phase II, Single-arm Trial of Sunitinib and Erlotinib in Advanced Renal Cell Carcinoma.
Zizhen Feng, Brendan D Curti, David I Quinn, John M Strother, Zunqiu Chen, Rebecca Agnor, Tomasz M Beer, Christopher W Ryan> ;Clinical Genitourinary Cancer. 2022 Oct 1
4 citations
Tissue based biomarkers in non-clear cell RCC: Correlative analysis from the ASPEN clinical trial
Susan Halabi, Qian Yang, Andrea Carmack, Shiqi Zhang, Wen-Chi Foo, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Rober...> ;Kidney Cancer Journal. 2021 Sep 30
3 citations
Correction: Angiokines Associated with Outcomes after Sunitinib or Everolimus Treatment in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert ...> ;Clinical Cancer Research. 2021 Jun 15
10 citations
Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Andrew J. Armstrong, Andrew B. Nixon, Andrea Carmack, Qian Yang, Tim Eisen, Walter M. Stadler, Robert Jones, Jorge A. Garcia, Ulka N. Vaishampayan, Joel Picus, Robert ...> ;Clinical Cancer Research. 2021 Jun 15
5 citations
Cabozantinib and dasatinib synergize to induce tumor regression in non-clear cell renal cell carcinoma.
Hui Wen Lue, Daniel S. Derrick, Soumya Rao, Ahna Van Gaest, Larry C. Cheng, Jennifer Podolak, Samantha Lawson, Changhui Xue, Devin Garg, Ralph White, Christopher W. Ry...> ;Cell Reports. Medicine. 2021 May 18
43 citations
A phase II basket trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: High-grade neuroendocrine neoplasm cohort.
Sandip Pravin Patel, Edward Mayerson, Young Kwang Chae, Jonathan R. Strosberg, Jue Wang, Bhavana Konda, Jourdain Hayward, Christine M. McLeod, Helen X. Chen, Elad Shar...> ;Cancer. 2021 Sep 1
30 citations
Active surveillance of metastatic renal cell carcinoma: Results from a prospective observational study (MaRCC)
Michael R. Harrison, Brian A. Costello, Nrupen A. Bhavsar, Ulka N. Vaishampayan, Sumanta K. Pal, Yousef Zakharia, Heather S.L. Jim, Mayer Fishman, Ana M. Molina, Chris...> ;Cancer. 2021 Jul 1
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarco...
Patel, S.,von Mehren, M.,Reed, D. R.,Kaiser, P.,Charlson, J.,Ryan, C. W.,Rushing, D.,Livingston, M.,Singh, A.,Seth, R.,Forscher, C.,D'Amato, G.,Chawla, S. P.,McCarthy,...> ;Cancer. 2019 Jun 08
ASO Author Reflections: Chemoradiation for High-Risk Soft Tissue Sarcomas.
Eric Lu, Christopher W. Ryan> ;Annals of Surgical Oncology. 2018 Oct 26
Mechanisms and funding opportunities in genitourinary cancer clinical research.
Christopher W. Ryan> ;Urologic Oncology. 2019 May 1
5 citations
Epirubicin and Ifosfamide with Preoperative Radiation for High-Risk Soft Tissue Sarcomas.
Eric Lu, Kelly Shea Perlewitz, James B. Hayden, Arthur Y. Hung, Yee Cheen Doung, Lara E. Davis, Atiya Mansoor, John T. Vetto, Kevin G. Billingsley, Andy Kaempf, Byung ...> ;Annals of Surgical Oncology. 2018 Jan 31
Doxorubicin plus Evofosfamide Versus Doxorubicin Alone in Locally Advanced, Unresectable or Metastatic Soft-Tissue Sarcoma (TH CR-406/SARC021): An International, Multi...
Sant P Chawla, Le D Cranmer, Brian A Van Tine, Robin L Jones, Scot Schuetze, Scot Okuno, Denise K Reinke, Mark Agulnik, Christopher W Ryan, Richard F Riedel> ;The Lancet.
26 citations
Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging.
Wei Huang, Brooke Beckett, Alina Tudorica, Janelle M. Meyer, Aneela Afzal, Yiyi Chen, Atiya Mansoor, James B. Hayden, Yee Cheen Doung, Arthur Y. Hung, Megan L. Holtorf...> ;Tomography. 2016 Dec 1
Preoperative therapy for extremity soft tissue sarcomas.
Davis LE, Ryan CW> ;Curr Treat Options Oncol. 2015 Jun
A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer.
Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, Van den Abbeele AD, Ryan CW, Beer TM, Loda M, Priolo C, Kantoff P, Taplin M> ;Clin Genitourin Cancer. 2015-04-01
10 citations
A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma.
Christopher W. Ryan, Chacon Matias, Mark Agulnik, Antonio Lopez-Pousa, Charles Williams, Dinesh P. de Alwis, Christopher Kaiser, Mary Alice Miller, Sabine Ermisch, Rob...> ;Investigational New Drugs. 2013 Feb 1
8 citations
A phase II study of everolimus in combination with imatinib for previously treated advanced renal carcinoma.
Christopher W. Ryan, Jacqueline Vuky, Joseph S. Chan, Zunqiu Chen, Tomasz M. Beer, Deirdre Nauman> ;Investigational New Drugs. 2011 Apr 1
Editorial comment.
Christopher W Ryan> ;The Journal of Urology. 2009 Dec 1
A phase II study of high-dose calcitriol combined with mitoxantrone and prednisone for androgen-independent prostate cancer.
Chan JS, Beer TM, Quinn DI, Pinski JK, Garzotto M, Sokoloff M, Dehaze DR, Ryan CW> ;BJU Int.. 2008-12-01
Join now to see all

Press Mentions

Analysis of Human Performance Deficiencies Associated with Surgical Adverse EventsJuly 3rd, 2019
SWOG Launches National Immunotherapy Clinical Trial for Rare CancersJanuary 18th, 2017